Intranasal administration of recombinant human SESN2 (rh‐SESN2) provides neuroprotective effects in hypoxic–ischemic encephalopathy by conditioning the AMPK/mTOR pathway in rat newborns [17]. This evidence concerns the gene SESN2 and brain ischemia.